Avexis Inc.'s manipulation of raw data in a mouse potency assay used as a product release test during the early clinical development of gene therapy Zolgensma (onasemnogene abeparvovec) allegedly involved two senior executives who altered or instructed others to alter a small amount of the data, the Novartis AG subsidiary said in an Aug. 23 response to an FDA Form 483 inspection report.